| 2.45 0.02 (0.82%) | 10-24 14:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.49  |
1-year : | 4.29 |
| Resists | First : | 2.99 |
Second : | 3.68 |
| Pivot price | 2.3 |
|||
| Supports | First : | 1.87 |
Second : | 1.56 |
| MAs | MA(5) : | 2.57 |
MA(20) : | 2.22 |
| MA(100) : | 2.05 |
MA(250) : | 2.32 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 53.1 |
| RSI | RSI(14): 59.6 |
|||
| 52-week | High : | 4.05 | Low : | 1.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GDTC ] has closed below upper band by 28.7%. Bollinger Bands are 117.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.65 - 2.67 | 2.67 - 2.68 |
| Low: | 2.29 - 2.31 | 2.31 - 2.32 |
| Close: | 2.41 - 2.43 | 2.43 - 2.45 |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Wed, 22 Oct 2025
CytoMed Therapeutics’ Chairman Boosts Stake Amid Biotherapeutics Growth - TipRanks
Wed, 22 Oct 2025
CytoMed Therapeutics (NASDAQ: GDTC) Chairman Now Owns 21.95%, 2,388,246 Shares - Stock Titan
Wed, 22 Oct 2025
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95% - GlobeNewswire
Tue, 14 Oct 2025
Second acquisition in a year — CytoMed bids for TC BioPharm assets to bolster allogeneic cell pipeline - Stock Titan
Tue, 14 Oct 2025
CytoMed Therapeutics Bids for TC BioPharm’s Assets Amid Strategic Expansion - TipRanks
Tue, 14 Oct 2025
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 68 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 28 (K) |
| Shares Short P.Month | 34 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | 0 % |
| Operating Margin | -452.2 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -42.4 % |
| Qtrly Rev. Growth | 101 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.06 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -9.96 |
| PEG Ratio | 0 |
| Price to Book value | 4.01 |
| Price to Sales | 40 |
| Price to Cash Flow | -9.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|